49,9%, lipid-lowering 22,7% and Antidiabetics the 6,1% of the total annual follow up medication cost . For the patients were subjected to ICD initial implantation antiplatelet-anticoagulants represent 24,4 %, antiarrhythmic 2,2 %, cardiovascular 44,2 %, lipid-lowering 25,0% and antidiabetics 4,1% of the total annual follow up medication cost. For the patients were subjected to ICD replacement antiplatelet-anticoagulants represent the 28,7 %, antiarrhythmic the 7,7 %, Cardiovascular 58,1 %, Lipid-lowering 5,5% and Antidiabetics 0,0% of the total annual follow up medication cost . ConClusions: The present study provides unique data regarding the percentage of annual medication cost attributed to each kind of treatment of unselected patients subjected to CRMDs implantation in a real-world setting. objeCtives: To estimate the cost-effectiveness of strategies for treatment deep vein thrombosis (DVT), the primary objective was to compare of effects of catheterdirected thrombolysis (CDT) and anticoagulation versus anticoagulation in the management of people with DVT of the lower limb. DVT occurs when a blood clot forms in a leg vein. The clot can break up and move to the lungs, leading to a potentially serious blockage in blood flow (pulmonary embolism). Because of the damage to the leg vein, post-thrombotic syndrome (PTS) may develop any time over the next couple of years. Methods: We used a Markov state transition decision model to evaluate the cost-effectiveness of treatment strategies using a societal perspective for costs, effectiveness-measured in incremental cost-effectiveness. Data sources included the English language literature using MEDLINE searches and bibliographies from selected articles. Results: Our study showed that CDT may have advantages over standard anticoagulation treatment. CDT effectively dissolved the clot so that complete clot breakdown occurred more often with CDT than with standard anticoagulant therapy. CDT and anticoagulation with compression stockings was associated with an effectiveness of 21.67 QALYs and a lifetime cost of $48 442. The incremental cost-effectiveness ratio (ICER) was $14 728/QALY gained. CDT increases the patency of veins and reduces the incidence of PTS following DVT by 35%. Strict eligibility criteria are necessary to reduce the risk of bleeding complications and this limits the applicability of this treatment. ConClusions: CDT and anticoagulation are highly cost-effective strategies for treatment patients with DVT and a low risk of bleeding. Use of strict eligibility criteria has improved the safety and acceptability of this treatment, with treatment directed by catheter in more extensive clots now the favoured method. objeCtives: To evaluate the economic value of dabigatran in the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recurrent events in comparison with other reimbursed oral anticoagulants warfarin and rivaroxaban from a perspective of Mexican public institutions. Methods: A Markov disease model with one month cycles length was developed. A number of parameters were followed in the model within the lifetime horizon (mean 18.2 years from diagnosis for Mexican patients), including efficacy and safety relevant events and treatment related costs. Main modelling outcome was life-years gained. Identical hypothetical cohorts of patients entered the model, following either acute index DVT or PE (500 simulations per treatment arm). Modelled efficacy endpoints (recurrent venous thromboembolic events, including DVT, fatal and non-fatal PE), safety endpoints (major and clinically relevant non-major bleeds) and treatment related adverse events were utilized from published results of head to head clinical trials or derived in network meta-analysis and indirect comparisons. Public institutional direct medical costs (2014 purchases and price tabulators) where retrieved to adopt the national health system perspective. Results: Mean life-years saved for dabigatran, warfarin and rivaroxaban were 4.478, 4.475 and 4.476 respectively. The highest cost of treatment was reported by rivaroxaban with 7,959.15 USD, followed by warfarin (7,923.31 USD) and dabigatran (7,748.46 USD). ICER showed dabigatran is a dominant alternative versus both rivaroxaban and warfarin. Results were robust to changes in discount rates. Dabigatran remained as a dominant alternative versus rivaroxaban and as a cost-effective one versus warfarin, in a price sensitivity analysis. ConClusions: From a perspective of Mexican public institutions, the treatment with dabigatran resulted to be a cost-saving alternative that could potentially increase life-years gained without increasing health care spends. objeCtives: Atrial fibrillation (AF) is the most common cardiac rhythm disorder; it increases stroke risk 5 to 6 times. Prevalence in Colombia has been estimated in 3.6% in population age 60 or over (some 180 000 potential patients). The aim of this study was to estimate cost-effectiveness of dabigatran 110 mg and 150 mg BID as a therapy for non valvular AF in Colombian population. Methods: From a third-party payer perspective (Colombian health system) we used a three-month cycle Markov model with six health states (and death): non-disabling stroke, disabling stroke, acute myocardial infarction and pulmonary embolism; two additional events were transient states: minor and mayor bleeding. Transition probabilities and proportion of events without CVEs for up to 3 years post-CVE, imposing a significant economic burden on U.S. commercial payers. objeCtives: Previous studies estimate that up to 15% of patients who undergo cardiovascular surgery require reoperation due to bleeding. The objective of this study is to estimate the incremental cost to hospitals for reoperations where a bleeding event is the primary reason across cardiovascular reconstructive surgeries. Methods: The study identified patients age 18 years or older with a record in the Premier hospital database between January 1, 2010 to September 30, 2012 who underwent cardiovascular reconstructive surgery. An algorithm (clinician expert rules and Premier Chargemaster data) was developed to define a reoperation where a bleeding event is the primary reason. Patients were excluded from analysis if extracorporeal circulation was utilized during the reoperation. The final sample included 294,548 patients in seven procedure groups: CABG, valve repair/replacement, AAA repair, AV access, endarterectomy, femoral-femoral/femoral-popliteal bypass, and other vascular. Multivariable modeling was performed to estimate the incremental effect on hospital costs for bleeding events that required reoperation. Regression models to control for age, gender, race, marital status, insurance type, and severity and mortality risk were performed for each category of cardiac and vascular reconstructive surgery. Results: Descriptive results indicated that average hospital visit costs with no reoperation ranged between $10,832 [SD $10,731] and $48,768 [$28,368] The incremental cost of reoperations for bleeding events in cardiac and vascular reconstructive surgery varied between 63% and 179% depending on the procedure group, with the largest increase for femoral-femoral bypass procedures, CABG, AAA repair, and valve procedures respectively. objeCtives: The objective of this investigation was to compare the contrasting results of recent cost-effectiveness analyses of statins. Methods: A systematic review of the literature on statin cost-effectiveness was conducted as per Cochrane methodology. Results: The four studies that met inclusion criteria reported variable conclusions about the cost-effectiveness of statin treatment, without a clear unanimity as to whether statins are cost-effective for primary prevention. All studies analyzed health care costs from the health care system perspective -inclusive of and limited to all direct medical costs to all payers resulting from the statin therapy. The time horizon varied from as 5 years to lifetime. Annual drug prices ranged from $770 to over $1,500 in 2006 dollars. The studies reported varying assessments of the cost-effectiveness of statins. Costs ranged from $590,000 to $3 to extend life by one year. Recently published studies found statin therapy more likely to be cost-effective. However, when each study's assumptions about statin costs were accounted, a substantial agreement among the authors was observed. Studies which assumed statins to be more costly found them to be less cost-effective, and vice-versa. Moreover, treatment of the lower risk groups appeared cost-effective as statins became cheaper. The studies were appraised using Philips and NICE checklist (qualitatively) and Quality of health economic studies (quantitatively). The studies were found to be of average quality. ConClusions: As the statins become generic, the chances of the patients at low risk for coronary disease may be treated costeffectively increases. It would be thus reasonable for clinicians to treat low-risk patients and statin therapy for a broader patient base, based on cost-effectiveness. objeCtives: To estimate the percentage of annual follow up medication cost attributed to each kind of treatment of unselected patients subjected to CRMDs implantation in a real-world setting. Methods: During a period of one year in total 464 (370 were subjected to PM implantation, 240 initial, 130 replacement and 94 to ICD implantation, 80 initial, 14 replacement) consecutive recipients were subjected to CRMD's implantation and furthermore were recruited and followed up for 1 year. At six and twelve months after the procedure of implantation we record the medication use for each patient. Results: For the patients were subjected in PM initial implantation antiplatelet-anticoagulants represent 24,5%, antiarrhythmic 1,1,%, cardiovascular 47,8%, lipid-lowering 22,6% and antidiabetics 3,9% of the total annual follow up medication cost. For the patients were subjected to PM replacement antiplatelet-anticoagulants represent 19,6%%, antiarrhythmic 1,7%, cardiovascular
objeCtives: To evaluate the economic value of dabigatran in the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recurrent events in comparison with other reimbursed oral anticoagulants warfarin and rivaroxaban from a perspective of Mexican public institutions. Methods: A Markov disease model with one month cycles length was developed. A number of parameters were followed in the model within the lifetime horizon (mean 18.2 years from diagnosis for Mexican patients), including efficacy and safety relevant events and treatment related costs. Main modelling outcome was life-years gained. Identical hypothetical cohorts of patients entered the model, following either acute index DVT or PE (500 simulations per treatment arm). Modelled efficacy endpoints (recurrent venous thromboembolic events, including DVT, fatal and non-fatal PE), safety endpoints (major and clinically relevant non-major bleeds) and treatment related adverse events were utilized from published results of head to head clinical trials or derived in network meta-analysis and indirect comparisons. Public institutional direct medical costs (2014 purchases and price tabulators) where retrieved to adopt the national health system perspective. Results: Mean life-years saved for dabigatran, warfarin and rivaroxaban were 4.478, 4.475 and 4.476 respectively. The highest cost of treatment was reported by rivaroxaban with 7,959.15 USD, followed by warfarin (7,923.31 USD) and dabigatran (7, 748.46 USD) . ICER showed dabigatran is a dominant alternative versus both rivaroxaban and warfarin. Results were robust to changes in discount rates. Dabigatran remained as a dominant alternative versus rivaroxaban and as a cost-effective one versus warfarin, in a price sensitivity analysis. ConClusions: From a perspective of Mexican public institutions, the treatment with dabigatran resulted to be a cost-saving alternative that could potentially increase life-years gained without increasing health care spends.
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Cost-EfECtiVEnEss of Dabigatran in non ValVular atrial fibrillation in ColoMbia
Triana J. J. 1 , Castañeda-Cardona C. 1 , Parada L. 2 , Rosselli D. 1 1 Pontificia Universidad Javeriana, Bogota, Colombia, 2 Boehringer Ingelheim, Bogota, Colombia objeCtives: Atrial fibrillation (AF) is the most common cardiac rhythm disorder; it increases stroke risk 5 to 6 times. Prevalence in Colombia has been estimated in 3.6% in population age 60 or over (some 180 000 potential patients). The aim of this study was to estimate cost-effectiveness of dabigatran 110 mg and 150 mg BID as a therapy for non valvular AF in Colombian population. Methods: From a third-party payer perspective (Colombian health system) we used a three-month cycle Markov model with six health states (and death): non-disabling stroke, disabling stroke, acute myocardial infarction and pulmonary embolism; two additional events were transient states: minor and mayor bleeding. Transition probabilities and proportion of events without CVEs for up to 3 years post-CVE, imposing a significant economic burden on U.S. commercial payers. The incremental cost of reoperations for bleeding events in cardiac and vascular reconstructive surgery varied between 63% and 179% depending on the procedure group, with the largest increase for femoral-femoral bypass procedures, CABG, AAA repair, and valve procedures respectively. objeCtives: The objective of this investigation was to compare the contrasting results of recent cost-effectiveness analyses of statins. Methods: A systematic review of the literature on statin cost-effectiveness was conducted as per Cochrane methodology. Results: The four studies that met inclusion criteria reported variable conclusions about the cost-effectiveness of statin treatment, without a clear unanimity as to whether statins are cost-effective for primary prevention. All studies analyzed health care costs from the health care system perspective -inclusive of and limited to all direct medical costs to all payers resulting from the statin therapy. The time horizon varied from as 5 years to lifetime. Annual drug prices ranged from $770 to over $1,500 in 2006 dollars. The studies reported varying assessments of the cost-effectiveness of statins. Costs ranged from $590,000 to $3 to extend life by one year. Recently published studies found statin therapy more likely to be cost-effective. However, when each study's assumptions about statin costs were accounted, a substantial agreement among the authors was observed. Studies which assumed statins to be more costly found them to be less cost-effective, and vice-versa. Moreover, treatment of the lower risk groups appeared cost-effective as statins became cheaper. The studies were appraised using Philips and NICE checklist (qualitatively) and Quality of health economic studies (quantitatively). The studies were found to be of average quality. ConClusions: As the statins become generic, the chances of the patients at low risk for coronary disease may be treated costeffectively increases. It would be thus reasonable for clinicians to treat low-risk patients and statin therapy for a broader patient base, based on cost-effectiveness.
PCV59 thE inCrEMEntal Cost of rEoPErations for blEEDing EVEnts in CarDiaC anD VasCular rEConstruCtiVE surgEry
PCV60 Cost EffECtiVEnEss of statins in PriMary PrEVEntion of Coronary hEart DisEasE: a systEMatiC rEViEw anD Quality assEssMEnt of EConoMiC EViDEnCE to EluCiDatE rECEnt trEnDs in usa
PCV62 annual MEDiCation Cost attributED to EaCh KinD of trEatMEnt of PatiEnts subjECtED to CrMDs iMPlantation
objeCtives: To estimate the percentage of annual follow up medication cost attributed to each kind of treatment of unselected patients subjected to CRMDs implantation in a real-world setting. Methods: During a period of one year in total 464 (370 were subjected to PM implantation, 240 initial, 130 replacement and 94 to ICD implantation, 80 initial, 14 replacement) consecutive recipients were subjected to CRMD's implantation and furthermore were recruited and followed up for 1 year. At six and twelve months after the procedure of implantation we record the medication use for each patient. Results: For the patients were subjected in PM initial implantation antiplatelet-anticoagulants represent 24,5%, antiarrhythmic 1,1,%, cardiovascular 47,8%, lipid-lowering 22,6% and antidiabetics 3,9% of the total annual follow up medication cost. For the patients were subjected to PM replacement antiplatelet-anticoagulants represent 19,6%%, antiarrhythmic 1,7%, cardiovascular objeCtives: To explore the cost-effectiveness of clopidogrel as secondary prevention in patients with a recent ischemic stroke (IS), or established peripheral arterial disease (PAD) compared with aspirin in China. Methods: A discrete event simulation was developed to evaluate the economic implications of secondary prevention with clopidogrel or aspirin, which are indicated for a patient with a recent MI, recent IS or established PAD. All available evidences were derived from clinical studies. Costs from Chinese health care perspective in 2013 US dollars and quality-adjusted life years (QALYs) were projected over a patient's lifetime. Uncertainties were addressed using sensitivity analyses. Results: Compared with aspirin, clopidogrel yielded marginal life expectancy by 0.46 and 0.21 QALYs at an incremental cost-effectiveness ratio of $5,246 and $9,890 per QALY in patients with a recent IS and PAD, respectively. One-way sensitivity analyses showed evaluation for patients with PAD and a recent IS was robust except the parameter of patient age. For the willingness to pay for $19,877 per QALY gained, clopidogrel intervention had a probability of 90% and 68% of being cost-effective for IS and PAD subgroups in comparison with aspirin, respectively. ConClusions: The analysis suggests that clopidogrel for the secondary prevention is cost effective for patients with either PAD or a recent IS in the Chinese setting in comparison with aspirin. objeCtives: Riociguat is the first product proven to improve health status in CTEPH patients. The objective of this study is to evaluate the cost-effectiveness of riociguat for patients with inoperable CTEPH or post-operative recurrent/persistent CTEPH in Turkey. Methods: A Markov model taking transitions of patients between functional classes and death state as core was adapted to Turkish setting. Turkish payer's perspective was taken and time-horizon was set as patient's lifetime (maximum 30 years) broken into four-month cycles. Riociguat was compared to placebo and common off-label treatments within the model. Essential clinical inputs were derived from CHEST-1 and CHEST-2 trials and local resource-utilization data were conducted through an expert panel. The incremental cost-effectiveness ratios (ICER) were calculated per life-years (LYs) gained and sensitivity of the results was analyzed for all comparators and placebo in terms of key inputs. All costs were calculated in Turkish Liras (TL) and converted to USD using TL/USD currency rate as 2. 1 (mid-2014) . Results: Total cost of riociguat-treated patients is 1,558, 7,342 and 59,706 USD higher compared to bosentan, ambrisentan and sildenafil respectively and 74,227 USD lower compared to iloprost. Besides, riociguat is associated with increments of 1.0034, 1.0878, 1.8174 and 1.8872 LYs compared to bosentan, ambrisentan, iloprost, sildenafil and placebo respectively. The ICER of riociguat per LYs gained compared to bosentan, ambrisentan, sildenafil and placebo were determined as 1,553 USD, 6,750 USD, 31,638 USD and 39,553 USD correspondingly. Model is sensitive only to the changes in "the starting age of the disease", yet not to an extent to affect the final results. ConClusions: Riociguat is cost-effective for CTEPH treatment compared to bosentan, ambrisentan, sildenafil and placebo with ICER values below the willingness-to-pay threshold (3-times GDP per capita ─ 32,346 USD) for Turkey. Furthermore, riociguat is pharmacoeconomically dominant to iloprost with lower costs and higher clinical effectiveness. objeCtives: The objective of this study was to compare the efficacy, complications, and costs associated with urokinase versus alteplase for the catheter-directed treatment of acute peripheral artery disease (APAD). Methods: The cost-effectiveness of catheter directed thrombolysis (CDT) with urokinase and alteplase for the treatment of APAD was compared using decision analysis. A literature-based decision model to evaluate cost-effectiveness was constructed. Successful treatment outcomes were defined as clot lysis with a subsequent 30-day survival posttreatment. Direct medical costs were assessed from the payer perspective in the Kazakhstan and analyzed using sensitivity analyses. A Monte Carlo analysis with 1000 patients was performed to obtain mean and incremental cost-effectiveness ratios (ICERs). Results: The mean cost-effectiveness ratio was $148 463 per treatment success for CDT with urokinase and $220 052 for CDT with alteplase. The ICER for alteplase relative to urokinase was $211 573 per additional CDT treatment success. Approximately 75% of simulated cases indicated that alteplase was associated with increased costs and increased treatment success compared with urokinase. Also, when using alteplase higher risk of bleeding than with urokinase, this complication is a major factor limiting the using of CDT. Results of a post hoc sensitivity analysis indicated that dominance decreased to approximately 10% of cases only under the most strict criteria. ConClusions: Decision analysis found an ICER of $211 573 per additional CDT treatment success for alteplase relative to urokinase in the treatment of APAD from the perspective of the payer in the Kazakhstan. In about 75% of cases resulting from a Monte Carlo simulation, alteplase was associated with increased costs and slightly increased CDT treatment success compared with urokinase, although this finding was sensitive to the distributional assumptions made concerning certain costs in the model. were extracted from the RELY trial; utilities were derived from the literature. Costs for medications and procedures were obtained from official government databases, all costs were in 2014 Colombian pesos (1 USD = 2000.33 COP) . Annual discount rate was 5% and we used a life time horizon (close to 20 years, on average). Costeffectiveness threshold was 3 times per capita GDP (around USD 22,500). Results: Compared with warfarin, patients treated with dabigatran 150 and 110 mg gained, on average 0.37 and 0.23 life-years, respectively, or 0.38 and 0.25 QALYs. The ICER for dabigatran 150 mg was USD 13,248 per QALY, and for dabigatran 110 mg was 23,621 per QALY. ConClusions: Dabigatran 150, compared with warfarin, the standard therapy, is cost-effective for ambulatory treatment of patients with non valvular AF. Dabigatran 110 ICER is discretely over the threshold (around 1000 USD).
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PCV66 EConoMiC EValuation of Dabigatran EtExilatE VErsus warfarin, riVaroxaban anD aPixaban in stroKE PrEVEntion in atrial fibrilation
Huicochea-Bartelt J. L. 1 , Gay-Molina J. 2 , Ortiz-Blas L. A. 2 , Herran S. 1 1 Boehringer Ingelheim, Distrito Federal, Mexico, 2 Tecnología e Informática para la Salud, Distrito Federal, Mexico objeCtives: To determine the economic value of dabigatran for stroke prevention in atrial fibrillation (SPAF) compared to other reimbursed oral anticoagulants warfarin, rivaroxaban and apixaban from a perspective of Mexican public institutions. Methods: A Markov disease model with three month cycles length was developed. A number of clinically relevant events, including acute thromboembolic and bleeding events, as well as long-term consequences such as stroke, intracranial hemorrhage and acute myocardial infarction, were followed in the model within the lifetime horizon (mean 10 years from diagnosis for Mexican patients). Identical hypothetical cohorts of patients entered the model, following a disease background of atrial fibrillation (2500 simulations per treatment arm). Published results of head to head clinical trials or relative efficacy derived in network meta-analysis and indirect comparisons were used to populate the model. Public institutional direct medical costs (2014 purchases and price tabulators) where retrieved to adopt the national health system perspective. Model outputs included total costs, event rates and life-years gained. Results: Mean life-years saved for dabigatran, apixaban, rivaroxaban and warfarin were 69.435, 69.219, 68.737 and 68.373 respectively. Estimated cost of treatment for dabigatran, warfarin, rivaroxaban and apixaban were 110,942 USD, 108,757 USD, 124,718 USD and 112,373 USD, respectively. ICER showed that dabigatran is a cost-saving alternative versus rivaroxaban and apixaban, and a cost-effective one versus warfarin (defined by a one GDP per capita threshold in the country). These results where robust to changes in discount rates. ConClusions: From a perspective of Mexican public institutions, the treatment with dabigatran was found to be cost-effective when compared with warfarin and economically dominant versus rivaroxaban and apixaban as it resulted in highest projected life years gained at lower costs.
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